ONE Enterprise (OTC:THDRF) Stock, Quote.Headers.trade-ideas

The ONE Enterprise PCL is engaged in the media business comprising digital TV, and radio, production of content, production of advertising media, rent of advertising space, subleasing television station, artist management, studio rental service, and sales of goods and investment in other business. Its operations are carried on only in Thailand.

THAI NVDR CO LTD NVDR by Thai NVDR Co Ltd.

The ONE Enterprise PCL

Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) reported better-than-expected second-quarter financial <a href="https://www.benzinga.com/quote/CRDO/earnings">results and issued strong guidance on Monday.</a>
Credo Technology reported quarterly earnings of 7 cents per share which beat the analyst consensus estimate of 5 cents per share. The company reported quarterly sales of $72.000 million which beat the analyst consensus estimate of $66.789 million.
Bill Brennan, Credo&#8217;s President and Chief Executive Officer, stated, &#8220;In the fiscal second quarter ended November 2, 2024 Credo generated record revenue of $72.0 million, up 21% sequentially and 64% year over year. The second quarter was our most successful to date across our three main product lines and Credo delivered total product revenue of $69.1 million. For the past few quarters, we have anticipated an inflection point in our revenues during the second half of fiscal 2025. I am pleased to share that this turning point has arrived, and we are experiencing even greater demand than initially projected, driven by AI deployments and deepening customer relationships.&#8221;
Credo Technology Group said it sees third-quarter revenue of $115 million to $125 million, versus market estimates of $86.042 million.
Credo Technology Group shares gained 46.1% to trade at $69.82 on Tuesday.
These analysts made changes to their price targets on Credo Technology Group following earnings announcement.
<ul>
<li>Needham analyst Quinn Bolton maintained Credo Technology with a Buy and raised the price target from $43 to $70.</li>
<li>B of A Securities analyst Vivek Arya upgraded the stock from Underperform to Buy and boosted the price target from $27 to $80.</li>
<li>Barclays analyst Thomas O&#8217;Malley maintained Credo Technology with an Overweight rating and raised the price target from $32 to $80.</li>
<li>Stifel analyst Tore Svanberg reiterated Credo Technology with a Buy and increased the price target from $50 to $75.</li>
<li>Craig-Hallum analyst Richard Shannon maintained the stock with a Buy and raised the price target from $38 to $75.</li>
</ul>
Considering buying CRDO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="602" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03130213/image-23-1024x602.png" alt="" class="wp-image-675051" style="width:560px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03130213/image-23-1024x602.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03130213/image-23-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03130213/image-23-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03130213/image-23.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42293707/jim-cramer-prefers-this-delivery-giant-over-ups">Jim Cramer Prefers FedEx Over This Delivery Giant That &#8216;Screwed Up A Lot Of Holiday Seasons&#8217;</a></li>
</ul>

Earnings

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CRDO

These Analysts Boost Their Forecasts On Credo Technology Group After Upbeat Results

<a href="https://event.webcasts.com/starthere.jsp?ei=1699221&amp;tp_key=063642a3e0&amp;tp_special=8" title="https://event.webcasts.com/starthere.jsp?ei=1699221&amp;tp_key=063642a3e0&amp;tp_special=8">https://event.webcasts.com/starthere.jsp?ei=1699221&amp;tp_key=063642a3e0&amp;tp_special=8</a>

Walmart CEO Says Seen Some Softness In Demand Post-Election In The United States

Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) shares are moving higher on Tuesday after the company announced a collaboration with Contemporary Amperex Technology. 
What To Know: The collaboration aims to promote the adoption and development of battery-swapping models, where consumers exchange a depleted battery for a full charged one, in the used car market. 
The companies will create a digital platform where consumers can buy and sell used new energy vehicles with the added option of battery swapping. Additionally, a marketplace will be established for swapping and purchasing batteries separately from the vehicles.
The companies will also provide services to inspect, certify and assess the condition of both the used cars and their batteries.
Kun Dai, Founder, Chairman and CEO of Uxin, commented, &#8220;We are thrilled to partner with Times Electric Service to drive innovation in the pre-owned new energy vehicle market. This collaboration aligns with our commitment to providing consumers with a professional, transparent, and reliable transaction experience. By meeting the diverse needs of consumers, we are creating long-term value for our customers and shareholders.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/12/42297400/nba-champ-jason-williams-says-marijuana-enhances-creativity-on-court-but-not-good-idea-before-game">NBA Champ Jason Williams Says Marijuana Enhances Creativity On Court But Not &#8216;Good Idea&#8217; Before Game</a>
UXIN Price Action: At the time of writing, Uxin shares are trading 19.6% higher at $5.04, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Pexels

Movers

UXIN

What's Going On With Uxin Shares Tuesday?

In the last three months, 4 analysts have published ratings on Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $111.0, a high estimate of $124.00, and a low estimate of $95.00. Observing a 3.5% increase, the current average has risen from the previous average price target of $107.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1733248857_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Thor Industries among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Rolle</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$124.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Tristan Thomas-Martin</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Thor Industries. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Thor Industries compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Thor Industries's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Thor Industries's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/THO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Thor Industries analyst ratings.</a>
<h2>Unveiling the Story Behind Thor Industries</h2>
Based in Elkhart, Indiana, Thor Industries manufactures Class A, Class B, and Class C motor homes along with travel trailers and fifth-wheel towables across about 35 brands. Through the acquisition of Erwin Hymer in 2019, the company expanded its geographic footprint and now produces various motorized and towable recreational vehicles for Europe, including motor caravans, camper vans, urban vehicles, caravans, and other RV-related products and services. The company has also begun generating revenue through aftermarket component parts via the acquisition of Airxcel in 2021; however, this is still a nascent part of the business as it accounts for less than 10% of total sales. In fiscal 2024, the company wholesaled 186,908 units and generated over $10 billion in revenue.
<h3>Breaking Down Thor Industries's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Thor Industries's financials over 3 months reveals challenges. As of 31 July, 2024, the company experienced a decline of approximately -7.45% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Thor Industries's net margin excels beyond industry benchmarks, reaching 3.55%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.23%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Thor Industries's ROA excels beyond industry benchmarks, reaching 1.26%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.28.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Thor Industries

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on BeiGene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $270.75, with a high estimate of $300.00 and a low estimate of $235.00. This upward trend is evident, with the current average reflecting a 19.27% increase from the previous average price target of $227.00.
<img src="https://www.benzinga.com/files/images/story/2024/1733248848_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of BeiGene by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Laaman</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$254.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$288.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to BeiGene. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of BeiGene compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of BeiGene's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of BeiGene's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BGNE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BeiGene analyst ratings.</a>
<h2>Unveiling the Story Behind BeiGene</h2>
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
<h3>Financial Insights: BeiGene</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: BeiGene's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 28.2%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -12.12%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): BeiGene's ROE excels beyond industry benchmarks, reaching -3.57%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): BeiGene's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.1%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: BeiGene's debt-to-equity ratio is below the industry average. With a ratio of 0.32, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGNE

A Glimpse Into The Expert Outlook On BeiGene Through 4 Analysts

A publicly traded Danish medical marijuana operator Stenocare announced Monday the approval of its innovative product, Astrum 10-10, for sale in Norway. This milestone paves the way for more patients to access the benefits of medical cannabis treatment. Astrum 10-10 is expected to become available to patients within the next 30 days.
&#8220;Our Astrum 10-10 oil was initially approved for sale in Australia and Germany and we are now proud to add Norway to the list," stated Stenocare CEO Thomas Skovlund Schnegelsberg. "We believe the new Astrum product represents a groundbreaking advancement for the entire medical cannabis industry and Norwegian patients alike. This innovative product directly addresses key challenges with bioavailability in patients, supported by robust data from a pharmacokinetic study in dogs that validates its benefits. With this milestone, Stenocare is firmly positioned as a first-mover in the next generation of medical cannabis oil products, poised to revolutionise the market.&#8221;
Stenocare has been collaborating with partners over the last five years to develop and test next-generation medical marijuana oil products. It is now ready to present its patented product to Norwegian patients.
Officially named "Astrum 10-10 Oil Stenocare," the product contains 10 mg/ml THC and 10 mg/ml CBD in a 30 ml bottle.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40251407/danish-cannabis-company-stenocare-to-launch-innovative-medical-marijuana-oil-in-germany">Danish Cannabis Company Stenocare To Launch &#8216;Innovative&#8217; Medical Marijuana Oil In Germany</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Astrum Oil Bioavailability</h2>
The Stenocare Astrum oil is based on technology designed to enhance the bioavailability of cannabinoids in the patient's bloodstream. This innovation aims to address a common challenge in medicine dosing by ensuring consistent uptake of active ingredients into the blood. With the Astrum product, Stenocare has successfully completed a pharmacokinetic (PK) study in dogs, documenting two critical parameters in the lymphatic system that can significantly improve bioavailability:
<ul>
<li>Parameter 1 – uptake in the blood: According to the PK study in dogs, Astrum improves blood uptake by a factor of 2.6 compared to a reference MCT-oil product on the market. When patients use traditional MCT-oil-based medical cannabis, the metabolism often reduces the uptake of cannabinoids in the body. As a result, a highly variable and often limited amount of active ingredients (i.e., cannabinoids) reaches the patient with a therapeutic effect. This creates difficulties in prescribing a consistent dosage to patients.</li>
</ul>
<ul>
<li>Parameter 2 – time to maximum effect: The PK study showed that the Stenocare Astrum product reduces the time from dosing to maximum effect from 2-4 hours to just 1 hour, providing a more consistent experience for patients.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40441445/3-years-after-cannabis-reform-in-malta-regulator-says-harm-reduction-approach-is-working-more-po">Norway: Green Party Leader Wants To Legalize Cannabis Use</a></li>
</ul>
Photo: Courtesy of Tinnakorn jorruang via Shutterstock

Cannabis

Danish Medical Marijuana Producer Stenocare To Launch Patented 10mg THC And 10mg CBD Oil In Norway

17 analysts have shared their evaluations of Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Accenture, presenting an average target of $379.59, a high estimate of $415.00, and a low estimate of $321.00. Observing a 7.68% increase, the current average has risen from the previous average price target of $352.53. 
<img src="https://www.benzinga.com/files/images/story/2024/1733248840_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Accenture. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$370.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$415.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$321.00</td>
</tr>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$415.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Jonathan Lee</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$395.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$390.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$389.00</td>
<td>$377.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Jason Kupferberg</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$388.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$370.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$395.00</td>
<td>$329.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$370.00</td>
<td>$376.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$329.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$365.00</td>
<td>$352.00</td>
</tr>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$405.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$321.00</td>
<td>$293.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$376.00</td>
<td>$330.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Accenture. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Accenture compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Accenture's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Accenture's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ACN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Accenture analyst ratings.</a>
<h2>About Accenture</h2>
Accenture is a leading global IT-services firm that provides consulting, strategy, and technology and operational services. These services run the gamut from aiding enterprises with digital transformation to procurement services to software system integration. The company provides its IT offerings to a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture employs just under 500,000 people throughout 200 cities in 51 countries.
<h3>Understanding the Numbers: Accenture's Finances</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3 months period, Accenture showcased positive performance, achieving a revenue growth rate of 2.63% as of 31 August, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.27%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Accenture's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 6.01%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.06%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.15.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Accenture Stands With Analysts

Ratings for Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Sprouts Farmers Market, presenting an average target of $129.82, a high estimate of $160.00, and a low estimate of $105.00. Witnessing a positive shift, the current average has risen by 14.44% from the previous average price target of $113.44.
<img src="https://www.benzinga.com/files/images/story/2024/1733248833_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Sprouts Farmers Market is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Morris</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$159.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$130.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$140.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$107.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Sprouts Farmers Market. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Sprouts Farmers Market compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Sprouts Farmers Market's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sprouts Farmers Market's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SFM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sprouts Farmers Market analyst ratings.</a>
<h2>About Sprouts Farmers Market</h2>
Sprouts Farmers Market Inc offers a unique specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment of better-for-you products paired with purpose-driven people. The company continues to bring the latest in wholesome, innovative products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in 23 states. It is one of the largest and fastest-growing specialty retailers of fresh, natural and organic food in the United States.
<h3>A Deep Dive into Sprouts Farmers Market's Financials</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Sprouts Farmers Market showcased positive performance, achieving a revenue growth rate of 13.57% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Sprouts Farmers Market's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.71% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.01%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sprouts Farmers Market's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.62%, the company showcases efficient use of assets and strong financial health.
Debt Management: Sprouts Farmers Market's debt-to-equity ratio is below the industry average at 1.23, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Sprouts Farmers Market Through The Eyes Of 11 Analysts

During the last three months, 6 analysts shared their evaluations of US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $107.0, with a high estimate of $120.00 and a low estimate of $90.00. A 3.17% drop is evident in the current average compared to the previous average price target of $110.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733248825_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of US Physical Therapy by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calvin Sternick</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Joanna Gajuk</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to US Physical Therapy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of US Physical Therapy compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into US Physical Therapy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/USPH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on US Physical Therapy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering US Physical Therapy: A Closer Look</h2>
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
<h3>Unraveling the Financial Story of US Physical Therapy</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: US Physical Therapy's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 12.02%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: US Physical Therapy's net margin excels beyond industry benchmarks, reaching 3.46%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): US Physical Therapy's ROE stands out, surpassing industry averages. With an impressive ROE of 1.2%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): US Physical Therapy's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.57% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: US Physical Therapy's debt-to-equity ratio is below the industry average. With a ratio of 0.53, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

USPH

Unveiling 6 Analyst Insights On US Physical Therapy

Innodata's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NYSE">INOD</a>) short percent of float has fallen 35.23% since its last report. The company recently reported that it has 2.47 million shares sold short, which is 9.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Innodata Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733248822_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Innodata has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Innodata's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Innodata's peer group average for short interest as a percentage of float is 2.73%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

INOD

Looking Into Innodata's Recent Short Interest

Zscaler's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NYSE">ZS</a>) short percent of float has fallen 13.64% since its last report. The company recently reported that it has 3.84 million shares sold short, which is 3.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zscaler Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733248817_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zscaler has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zscaler's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zscaler's peer group average for short interest as a percentage of float is 5.15%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Zscaler's Recent Short Interest

F5's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NYSE">FFIV</a>) short percent of float has fallen 10.72% since its last report. The company recently reported that it has 2.09 million shares sold short, which is 4.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.91 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>F5 Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733248811_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for F5 has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing F5's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, F5's peer group average for short interest as a percentage of float is 7.02%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

FFIV

Looking Into F5's Recent Short Interest

Throughout the last three months, 4 analysts have evaluated Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $12.5, along with a high estimate of $17.00 and a low estimate of $8.00. Surpassing the previous average price target of $9.75, the current average has increased by 28.21%.
<img src="https://www.benzinga.com/files/images/story/2024/1733248810_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Alignment Healthcare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$8.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alignment Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alignment Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Alignment Healthcare's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Alignment Healthcare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ALHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alignment Healthcare analyst ratings.</a>
<h2>Delving into Alignment Healthcare's Background</h2>
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
<h3>Alignment Healthcare's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Alignment Healthcare displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 51.61%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Alignment Healthcare's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -3.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Alignment Healthcare's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -22.17%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Alignment Healthcare's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.75%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 1.92, Alignment Healthcare faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALHC

4 Analysts Have This To Say About Alignment Healthcare

CleanSpark Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) shares were down on Tuesday, even after the company reported <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42289072/zscaler-transmedics-group-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session">upbeat fourth-quarter results</a>.
The company reported its results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<h1 class="wp-block-heading">HC Wainwright On CleanSpark</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61d4371c30778300016abc55/mike-colonnese">Analyst Mike Colonnese</a> reiterated a Buy rating and price target of $27.
CleanSpark, a Bitcoin mining company that offers investors "pure-play exposure" to the world's largest crypto, reported "solid" results for the fourth quarter and fiscal 2024, Colonnese said in a note.
"FY2024 was another strong year of execution for CLSK," with the company growing total deployed capacity by 187% year-on-year to 27.6 EH/s at the end of September versus an average of around 75% for its peers, the analyst stated. CleanSpark also improved its overall fleet efficiency by 23%, he added.
The company's revenue grew by 125% to $379 million on total Bitcoin production of 7,098 for the year. Its adjusted EBITDA and margins grew to $246 million and 65%, respectively, "a significant improvement from $25M/15% in the prior year on higher BTC prices and lower power costs," Colonnese wrote.
Management reiterated their prior calendar year 2024 and 2025 guidance of 37 EH/s and 50 EH/s, respectively.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">JPMorgan On CleanSpark</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/611bba00b4035700018b67b6/reginald-smith">Analyst Reginald Smith</a> reiterated a Neutral rating on the stock.
CleanSpark's coins mined and total revenues declined on a sequential basis, with slightly lower Bitcoin prices, Smith said. "Cash operating expenses ticked higher sequentially, which does not come as a big surprise given CleanSpark's recent geographic expansion and the close of the GRIID acquisition," he added.
Management reiterated its commitment to reaching 50 EH/s in 2025, the analyst stated. "All told, it was a solid, albeit relatively quiet, quarter, and CleanSpark seems ready to reuse its greenfield expansion and M&amp;A playbook in 2025 to continue growing hashrate," he further wrote.
CLSK Price Action: Shares of CleanSparkhad declined by 3.37% to $14.02 at the time of publication on Tuesday.
Read More: • <a href="https://www.benzinga.com/24/12/42294962/whats-going-on-with-bitcoin-mining-stock-cleanspark-tuesday">What&#8217;s Going On With Bitcoin Mining Stock CleanSpark Tuesday?</a>
Photo: Anucha Cheechang on Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings Beats

Reiteration

CLSK

Bitcoin Miner CleanSpark Has 'Solid, Albeit Relatively Quiet' Quarter, Ready For Growth, Says Analyst

Redburn Atlantic analyst Simon Clinch upgrades Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Neutral to Buy and raises the price target from $37 to $95.

Upgrades

UPST

Redburn Atlantic Upgrades Upstart Hldgs to Buy, Raises Price Target to $95

TikTok Shop saw more than $100 million in sales on Black Friday, as the social media app's bet on live shopping in the US appears<a href="https://www.benzinga.com/government/24/10/41380181/alibabas-lazada-leverages-ai-in-e-commerce-race-against-shopee-and-tiktok-shop"> to be paying off. </a>
What To Know: TikTok launched its Shop e-commerce platform in the fall of 2023 and has been pushing its creators and sellers to adopt the live shopping format which drives billions in sales in other markets, like China.&nbsp;
&#8220;We want people to discover new products,&#8221; Nico Le Bourgeois, TikTok Shop&#8217;s head of US operations, <a href="https://www.businessinsider.com/tiktok-drove-100-million-in-us-black-friday-sales-livestream-2024-12">told</a> Business Insider in late October. 
&#8220;To be surprised. To feel like shopping can be different. And as a part of that, if we can have many customers shop in live and realize that this is really cool, I think we will have done a good job.&#8221;
Read More: <a href="https://www.benzinga.com/etfs/new-etfs/24/12/42270723/new-conservative-etf-aims-to-invest-in-sp-500-without-dei-were-going-to-deliver-that-mandate">New Conservative ETF Aims To Invest In S&amp;P 500 Without DEI: &#8216;We&#8217;re Going To Deliver That Mandate&#8217;</a>
U.S. shoppers participated in more than 30,000 live shopping streams on Friday alone. Home goods, fashion and beauty products are among the most popular categories.
Canvas Beauty, a seller of hair-care products on TikTok Shop, hit $1 million in sales within two hours of going live on the app, the company said.
Sellers are joining TikTok Shop as a way to diversify their revenue streams from other sites like Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). CNBC <a href="https://www.cnbc.com/2024/12/02/amazon-sellers-are-flocking-to-tiktok-shop-despite-looming-us-ban.html">reports that</a> TikTok Shop was a hot topic at a conference for Amazon sellers in October. A session on "how to scale your brand" with TikTok Shop drew a full room of Amazon sellers.  
"Amazon comes with a ton of competition," e-commerce strategist Rafay MH told the crowd at the conference. "TikTok is the opportunity for free eyeballs and sales."
Salesforce <a href="https://www.benzinga.com/news/retail-sales/24/12/42257394/temu-and-shein-are-shaking-up-western-retailers-this-holiday-season">estimates that</a> one in five online holiday purchases in the U.S., U.K., Australia, and Canada will be made through online marketplaces like Shein, Temu, TikTok Shop, and AliExpress. 
Potential TikTok Ban: President Joe Biden signed a bill in April that requires parent company ByteDance to sell TikTok by Jan. 19. Without a sale of TikTok, app stores and internet hosting services will be prohibited from offering the app in the U.S. 
President-elect Donald Trump has flip-flopped on the issue of a TikTok <a href="https://www.benzinga.com/news/24/09/40890877/tiktoks-future-hangs-in-balance-as-judges-express-skepticism-in-us-court-battle">ban</a> and the future remains uncertain for the app. 
Creators continue to flock to TikTok and sellers seem to be taking the looming ban of the app in stride. 
"The sellers here, creators, they're building their livelihoods on TikTok," a TikTok spokesperson told CNBC. "We're going to continue to show up for that. There's a huge opportunity for us."
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42273676/walmart-target-bath-body-works-stand-out-as-black-friday-winners-analysts">Walmart, Target, Bath &amp; Body Works Stand Out As Black Friday Winners: Analysts</a></li>
</ul>
Image: Shutterstock

Large Cap

Social Media

General

AMZN

TikTok Shop Bags More Than $100 Million In Black Friday Sales With Potential Ban Ahead

<a href="https://reinvent.awsevents.com" title="https://reinvent.awsevents.com">https://reinvent.awsevents.com</a>

Amazon Says Customers Can Use Amazon Nova-powered Generative AI Apps To Understand Videos

Michael Pollan, the celebrated food reform advocate, stirred controversy this week after <a href="https://www.theamericanconservative.com/theyre-lying-about-robert-f-kennedy-jr/">sharing an article</a> on Robert F. Kennedy Jr. in The American Conservative. In a recent <a href="https://www.politico.com/news/magazine/2024/11/21/michael-pollan-not-endorsing-rfk-00190878">interview</a> with Politico, Pollan discussed the nuances of his views on RFK Jr., especially when it comes to Kennedy's stance on vaccines and, crucially, his views on psychedelics.
<h3 class="wp-block-heading">Food Reform Only Common Ground</h3>
Pollan aligns with Kennedy on issues like eliminating <a href="http://v">ultra-processed foods</a> from school lunches and challenging agricultural subsidies that promote unhealthy diets. "The way we're eating is the biggest threat to public health," Pollan said, acknowledging that Kennedy's criticisms echo his own long-standing arguments about diet-related diseases.
However, Pollan quickly clarified that he does not support <a href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics">Kennedy's nomination</a> as Secretary of Health and Human Services (HHS), primarily due to Kennedy's stance on vaccines. "I think he's completely unfit," Pollan said, highlighting the risks posed by vaccine misinformation.
<h3 class="wp-block-heading">An Anti-Science Psychedelics Supporter?</h3>
Pollan, who helped bring <a href="https://www.benzinga.com/markets/psychedelics">psychedelics</a> into the mainstream with his book <a href="https://www.benzinga.com/markets/cannabis/22/07/28233108/how-to-change-your-mind-michael-pollan-on-berkeleys-new-center-for-the-science-of-psychedelics-p">How to Change Your Mind</a>, expressed deep concern about Kennedy's potential influence on the psychedelic movement. While Kennedy has shown support for <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted therapy</a>, Pollan fears that associating psychedelics with Kennedy's anti-science views on vaccines and fluoride could hurt the movement&#8217;s legitimacy.
"The fact that someone this high up in this administration is supportive of psychedelic-assisted therapy is encouraging in one way," Pollan explained. "But in another, I think it could be very dangerous to the movement, because if the science of psychedelics gets tangled up with the anti-science agenda around vaccines or fluoride, that could do long-term damage to psychedelics."
Pollan's main concern is that the connection could make psychedelics, which are <a href="https://www.benzinga.com/markets/cannabis/23/10/35241585/revolutionizing-psychiatry-more-than-80-of-psychiatrists-see-promise-in-psychedelics-or-hallucin">a promising treatment</a> for conditions like PTSD, seem "kooky" and undermine their scientific credibility. "Psychedelics should be approved because the science is good, not because they have a fan in the White House," Pollan emphasized. He also cautioned against hoping that figures like Kennedy would force the <a href="https://www.benzinga.com/topic/food-and-drug-administration">FDA</a> to approve psychedelics before the science is fully established.
<h3 class="wp-block-heading">FDA And MDMA: A Delicate Situation</h3>
Pollan also addressed the FDA's decision to <a href="https://www.benzinga.com/markets/cannabis/24/08/40300943/fda-rejects-mdma-for-ptsd-treatment-calls-for-more-research-on-psychedelic-therapy">reject MDMA-assisted therapy for PTSD</a> earlier this year, calling it a "big hiccup." However, he remains optimistic that approval is forthcoming as more research is conducted. "If the science is as good as the promoters think it is, then it will be approved under its own steam, without forcing it down the throat of the FDA," Pollan said.
<h3 class="wp-block-heading">Political Realities And Future Reform</h3>
Although Pollan acknowledges Kennedy's role in raising important food system issues, he remains skeptical that he would be effective as HHS Secretary. "I don't see Trump getting behind such an agenda," Pollan said, noting that the deregulatory environment under the current administration would likely hinder any major food reform initiatives.
Despite his reservations, Pollan said he hopes that food reform will gain more attention in the future. He pointed to the growing concerns of parents about the food system, particularly in schools. "There's a lot of support for this issue, and hopefully, some of these ideas will take on a life of their own." 
Cover image Ringo Chiu / Shutterstock

Government

Psychedelics

Media

RFK Jr.'s Anti-Science Views 'Could Be Very Dangerous' For Psychedelics Movement Says Michael Pollan

Automated Reasoning checks, multi-agent collaboration, and Model Distillation build on the strong foundation of enterprise-grade capabilities available on Amazon Bedrock to help customers go from proof of concept to production-ready generative AI faster

AWS Announces New Capabilities For Amazon Bedrock

Stephens &amp; Co. analyst Scott Fidel upgrades Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) from Equal-Weight to Overweight and raises the price target from $13 to $17.

Comments

ONE Enterprise

ONE Enterprise (THDRF) Forecast

ONE Enterprise (OTC:THDRF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga